Literature DB >> 28905567

[Application of high performance liquid-ion trap mass spectrometry in analyzing saponins in sodium aescinate].

Xiao-Hong Song1, Wei-Hao Wang1, Shi-Tao Chen1, Sha Chen1, Jun Zhang1, Yue-Sheng Wang1, An Liu1.   

Abstract

Sodium aescinate, which is produced from saponins of Chinese Buckeye Seed, is a prescription drug for treatment of brain edema and all kinds of swellings caused by surgery. In this article, high-performance liquid chromatography/ion trap (HPLC-IT) mass spectrometry was applied to study the characteristic ions of ten reference substances, namely escin Ⅰa, escin Ⅰb, isoescin Ⅰa, isoescin Ⅰb, aesculiside A, aesculiside B, aesculuside A, escin Ⅳc, escinⅡa and escin Ⅴ, which were isolated from aescinate. Furthermore, 19 saponin compounds were predicted in sodium aescinate, besides the above mentioned reference substances. The study showed that sapogenins in sodium aescinate had two structural types, namely protoaescigenin and barringenol C, and the substituent acetyl, tigloyl or angeloyl was usually located at C-21, C-22 or C-28 position. Among these predicted saponins, their sugar chains were all located at C-3 position consisting of glucose and glucuronide. This study provides experimental data for chemical constituents in sodium aescinate and scientific basis for quality and safety evaluation. Copyright© by the Chinese Pharmaceutical Association.

Entities:  

Keywords:  Chinese Buckeye Seed ; HPLC-IT mass spectrometry ; saponins ; sodium aescinate

Mesh:

Substances:

Year:  2016        PMID: 28905567     DOI: 10.4268/cjcmm20161313

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  1 in total

1.  Modification of sodium aescinate into a safer, more stable and effective water-soluble drug by liposome-encapsulation: an in vitro and in vivo study.

Authors:  Sifan Huang; Xinyu Wang; Mengmeng Liu; Zhizhe Lin; Wenqian Gu; Haili Zhao; Yanqiu Zhang; Baoyue Ding; Jiyong Liu; Xin Wu; Wei Fan; Jianming Chen
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.